TABLE 2.

Multivariable Cox proportional hazards analysis for overall survival among PV and ET patients.

	Propensity score matching				Inverse probability of treatment weighting
Statin use	N	HR	95% CI	p	N	HR	95% CI	p
Primary analysis
Overall
Never	1645	1.00			1771	1.00
Ever	1645	0.78 a	0.63–0.98	0.03	2239	0.79 b	0.64–0.97	0.03
PV
Never	727	1.00			798	1.00
Ever	727	0.94 c	0.69–1.29	0.71	1011	0.82 b	0.59–1.14	0.24
ET
Never	888	1.00			973	1.00
Ever	888	0.79 c	0.60–1.05	0.10	1228	0.77 b	0.59–1.02	0.07
Sensitivity analysis
Overall
Never	582	1.00			1708	1.00
Ever	582	0.59 d	0.50–0.71	<0.01	584	0.66	0.57–0.77	<0.01
PV
Never	267	1.00			772	1.00
Ever	267	0.68 e	0.52–0.90	0.01	269	0.76 f	0.61–0.96	0.02
ET
Never	314	1.00			936	1.00
Ever	314	0.60 g	0.47–0.76	<0.01	315	0.61 h	0.50–0.76	<0.01

Abbreviations: CI, confidence interval; ET, essential thrombocythemia; HR, hazard ratio; N, number of patients; PV, polycythemia vera.

^a Adjusted for use of statins before diagnosis and history of thrombosis in the model.

^b Adjusted for use of statins before diagnosis.

^c Adjusted for use of statins before diagnosis, history of thrombosis and Elixhauser comorbidity score in the model.

^d Adjusted for age at diagnosis, Yost index in the model.

^e Adjusted for history of thrombosis in the model.

^f Adjusted for receipt of influenza vaccination in the 12 months before diagnosis in the model.

^g Adjusted for race and disability status in the model.

^h Adjusted for age at diagnosis in the model.